Discontinue use if serious allergic or anaphylactic reactions occur. Not to be initiated in patients w/ ANC <1 x 109
cells/L, ALC <0.5 x 109
cells/L or Hb <8 g/dL. Not to be given in patients w/ active TB. Increased risk of malignancies including lymphoma. Active, chronic or recurrent infections; previously untreated latent TB; viral reactivation; DVT/pulmonary embolism, patients undergoing surgery & immobilisation. Assess lipid parameters approx 12 wk following initiation of therapy & thereafter. Not recommended w/ live, attenuated vaccines during or prior to treatment; biologic DMARDs, immunomodulators or other Janus kinase inhibitors; potent immunosuppressives eg, azathioprine, tacrolimus, ciclosporin. Increased ALT or AST during treatment; drug-induced hepatic injury. Not recommended in severe hepatic & renal impairment. May decrease female fertility. Women of childbearing potential should use effective contraception during & at least 1 wk after last dose. Not to be used during lactation. Childn & adolescents 0-18 yr. Increased risk of lymphocytosis in elderly w/ RA.